Calcium, Phosphorus and PTH in Patients with End Stage of Chronic Kidney Disease, Undergoing Hemodialysis

  • Serfa Faja PhD candidate in medical sciences
  • Amir Shoshi

Abstract

Renal hyperparathyroidism (rHPT) is a common complication of chronic kidney disease characterized by elevated parathyroid hormone levels secondary to derangements in the homeostasis of calcium, phosphate, and vitamin D. Patients with rHPT experience increased rates of cardiovascular problems and bone disease. The Kidney Disease: Improving Global Outcomes guidelines recommend that screening and management of rHPT be initiated for all patients with chronic kidney disease stage 3 (estimated glomerular filtration rate, - 60 mL/min/1.73 m2). Since the 1990s, improving medical management with vitamin D analogs, phosphate binders, and calcimimetic drugs has expanded the treatment options for patients with rHPT, but some patients still require a parathyroidectomy to mitigate the sequelae of this challenging disease.
Published
Mar 15, 2020
How to Cite
FAJA, Serfa; SHOSHI, Amir. Calcium, Phosphorus and PTH in Patients with End Stage of Chronic Kidney Disease, Undergoing Hemodialysis. European Journal of Medicine and Natural Sciences, [S.l.], v. 4, n. 1, p. 48-66, mar. 2020. ISSN 2601-6400. Available at: <http://journals.euser.org/index.php/ejmn/article/view/4768>. Date accessed: 07 mar. 2021.